Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
7.12
+0.17 (2.45%)
Nov 22, 2024, 4:00 PM EST - Market closed
Vir Biotechnology Revenue
Vir Biotechnology had revenue of $2.38M in the quarter ending September 30, 2024, a decrease of -9.81%. This brings the company's revenue in the last twelve months to $78.62M, down -33.82% year-over-year. In the year 2023, Vir Biotechnology had annual revenue of $86.18M, down -94.67%.
Revenue (ttm)
$78.62M
Revenue Growth
-33.82%
P/S Ratio
12.29
Revenue / Employee
$133,932
Employees
587
Market Cap
980.57M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AMN Healthcare Services | 3.07B |
Phibro Animal Health | 1.05B |
Collegium Pharmaceutical | 599.25M |
HealthStream | 287.99M |
Weave Communications | 195.84M |
Gyre Therapeutics | 105.03M |
VIR News
- 4 days ago - Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program - Business Wire
- 5 days ago - Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - Business Wire
- 8 days ago - Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting - Business Wire
- 18 days ago - Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off - Seeking Alpha
- 22 days ago - Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Business Wire
- 5 weeks ago - Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024 - Business Wire
- 5 weeks ago - Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD's The Liver Meeting® 2024 - Business Wire